The Pro series cover 1012 genes for targeted therapy, immunotherapy, chemotherapy, and genetic risks. Using next-generation sequencing (NGS) technology of target gene capture, it comprehensively and accurately detects target gene capture exons and single nucleotide variations (SNV), short fragment insertion or deletion variations (InDel), gene copy number variations (CNV) and gene rearrangement/fusion within the intron range of standard spliceosomes. It also evaluates immune indicators such as TMB and MSI. Using immunohistochemistry (IHC) technology, it detects the representative indicator PD-L1 of tumor immune-microenvironment and provides reference and guidance for clinical medication and genetic risk of solid tumor patients.
▪ Covers 116 genes related to targeted therapy for solid tumor that have been approved by FDA/NMPA, recommended in NCCN guidelines, or have shown clinically significant potential in clinical trials, and evaluates multiple targeted drugs for solid tumor that have been approved or in phase II/III clinical trials
▪ Covers genes related to multiple signaling pathways for tumor occurrence and development
▪ Covers 37 HRR genes and assesses the efficacy of PARP inhibitors
▪ The bTMB uses a machine learning model that is highly consistent with the tissue TMB (0.90)
▪ Covers 109 chemotherapy genes related to Asian/Chinese populations and assesses the efficacy and toxicity risks of chemotherapy drugs
▪ Covers gene germline interpretation and prompts genetic risks
▪ The mutation information is accurately described according to the HGVS standard terms. The germline genetic mutations are classified according to the ACMG guidelines for the classification of the pathogenicity of mutations, and the clinical medication is suggested based on clinical based medical evidence
▪ Ultra-high depth sequencing and the limit of detection of ctDNA is 0.1%
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
